Treatment of Severe Uncontrolled Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) with Mepolizumab or Dupilumab: A Preliminary Single-Center Study for Evaluation of Safety and Efficacy.

J Pers Med · 2026 · PMC13118264 · PMID 42042591

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

almost significantp = 0.057so close (0.05 < p ≤ 0.1)

A comparison of overall complications between the treatment groups resulted in almost significant ( p = 0.057), with 24.4% of complications in the Dupilumab group vs. 6.5% in the Mepolizumab group [ SM: Table S44 ].

also in 1,858 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.